

Sarborg Files Solid-Form Patent on Major First-in-Class Respiratory Asset, Opening New Multi-Indication Opportunities

WILMINGTON, De - October 14, 2026 - Sarborg Limited ("Sarborg" or the "Company") today announced the filing of a new patent application covering novel solid forms of a major, first-in-class respiratory medicine. The filing further expands the Company's rapidly growing portfolio of patented solid-form assets.

The newly identified solid forms are highly distinctive. Not every established molecule is amenable to new solid forms, and the Company had not anticipated that forms of this kind would be achievable for this compound. Their discovery gives Sarborg a differentiated intellectual property position on an asset with substantial known potential for expansion well beyond its current approved use.

The new solid forms are designed to improve key physicochemical properties such as solubility, stability and formulation flexibility, potentially supporting new formulations, delivery routes and dosing approaches. Sarborg's Quantum Signature Agent has also identified multiple additional high-potential indications across respiratory and inflammatory disease. The Company is analyzing combination therapies with the objective of generating further patentable compositions.

The compound's current indication sits within a global treatment market estimated at more than \$20 billion annually, with the additional indications identified by Sarborg representing further significant opportunities. Sarborg intends to progress the new solid forms through characterization and early in-vitro studies, building a data package to support licensing and partnership discussions.

“This is one of the most significant filings in Sarborg's portfolio to date,” said Dr. Andrew Regan, Chief Executive Officer of Sarborg. “We have secured novel solid forms of a first-in-class medicine with enormous potential, forms we did not expect to find, and our agentic and quantum models have already mapped where that potential could be realized. We believe this creates a compelling opportunity for the asset and for Sarborg.”

About Sarborg Limited

Sarborg is an agentic AI and quantum computing signature intelligence business, built on the principle that signatures can function as a universal data language to identify, interpret, and generate high-value opportunities across multiple sectors. By analysing, matching, and learning from biological, chemical, and industrial signatures using its agentic AI and quantum computing infrastructure, Sarborg's agents create a continuously evolving network of intelligence-driven insights.

Investors & Media:

info@sarborg.com

www.sarborg.com